Curexo signed an agreement on Thursday to sell four of its artificial joint surgery robots to CU Medical. The accord calls for Curexo to provide CU Medical with three TSolution One, a new surgery robot, and one ROBODOC, a first-generation surgery robot.
|Curexo CEO Lee Jae-jun (second from left) and CU Medical CEO Nah Hak-rok hold up their MOU at CU Medical headquarters in Wonju, Gangwon Province, on Friday.|
Also, the company will conclude a memorandum of understanding with CU Healthcare, a subsidiary of CU Medical, to promote advanced medical devices and pursue innovative growth through such machinery.
CU Healthcare, which focuses on the management services organizations (MSO) business, will select a medical institution that can effectively use TSolution One, and Curexo will designate the hospital as an Asian education center to encourage surgeons and promote technology exchanges between domestic and foreign physicians.
Through this process, CU Healthcare will enhance its competitiveness with differentiated professional management and Curexo will use its network to distribute its products.
“We will actively cooperate to make the most of resources possessed by each other to maximize mutual benefits,” a Curexo company official said.
The official also noted that the TSI, its U.S. subsidiary, plans to complete the ongoing knee clinical trials in the United States this week.
“We expect the global expansion of TSolution One after the FDA approval in 2019,” he said. “The company is also running smoothly with its goal to become a company that can manufacture its models of surgery robots.
<© Korea Biomedical Review, All rights reserved.>